Skip to main content
Clinical Trials/NCT01161485
NCT01161485
Completed
N/A

Reduction of Drug Use and HIV Risk Among Out-of-Treatment Methamphetamine Users

University of Colorado, Denver1 site in 1 country502 target enrollmentAugust 2010
ConditionsHIV Infections

Overview

Phase
N/A
Intervention
Not specified
Conditions
HIV Infections
Sponsor
University of Colorado, Denver
Enrollment
502
Locations
1
Primary Endpoint
Reduction of HIV and STI risk behaviors, specifically sex risk behaviors but also needle risk for injection drug users
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

There is a need to identify and test effective strategies to reduce meth use and human immunodeficiency virus (HIV) risk behaviors in heterosexuals. This project will compare the efficacy of a manually-driven HIV testing and counseling (HIV T/C) intervention, with HIV T/C plus a manualized Contingency Management (CM), with HIV T/C plus CM plus a manualized Strengths-Based Case Management (CM/SBCM) model. As HIV T/C is the standard of care, the investigators are testing to determine if the investigators can enhance this standard. The specific aims and hypotheses of this protocol are:

  1. To compare the relative efficacy of HIV T/C vs. CM vs. CM/SBCM on reducing drug use, specifically meth use. Hypothesis 1: CM/SBCM will reduce drug use more than those in CM (which will have more reduction than HIV T/C), potentially mediated through increased service utilization.
  2. To compare the relative efficacy of HIV T/C vs. CM vs. CM/SBCM on reducing HIV and STI risk behaviors, specifically sex risk behaviors but also needle risk for injection drug users (IDUs). Hypothesis 2: CM/SBCM will have greater decreases in HIV risk behaviors than those in CM (which will have greater decreases than HIV T/C), potentially mediated through reduced drug use.
  3. To compare the relative efficacy of HIV T/C vs. CM vs. CM/SBCM on improving mental health status. Hypothesis 3: CM/SBCM will have greater improvements in mental health status than those in CM (which will have greater improvements than HIV T/C), potentially mediated through increased service utilization and reduction of drug use, and potentially moderated by baseline meth use.
Registry
clinicaltrials.gov
Start Date
August 2010
End Date
May 25, 2016
Last Updated
9 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • 18 years of age or older
  • Be competent (not too intoxicated or mentally disabled) to give informed consent at the time of the interview
  • Meth use (verified through urine drug screening and a self-report of meth use of at least 4 times per month for the last 3 months)
  • Self-reported sex with someone of the opposite sex in last 30 days
  • Ability to provide a reliable address and phone number for contact
  • Not in drug treatment in the past 30 days
  • Willingness to be tested for HIV at baseline and follow-up
  • Not transient and no know reason why he/she will not be available for follow-up interviews
  • Not currently mandated by the criminal justice system to receive treatment based on self-report.

Exclusion Criteria

  • Participation in drug treatment in the past 30 days
  • Currently participating in another Project Safe study
  • Pregnant or attempting to become pregnant
  • Intoxicated or impaired mentally to the point that they cannot voluntarily consent to participate tin the project and/or respond to the interview

Outcomes

Primary Outcomes

Reduction of HIV and STI risk behaviors, specifically sex risk behaviors but also needle risk for injection drug users

Time Frame: 12-month follow-up interview

Improved mental health status

Time Frame: 12-month follow-up interview

Reduction of drug use, specifically methamphetamine

Time Frame: 12-month follow-up interview

Study Sites (1)

Loading locations...

Similar Trials